MigraineMind research summary
A Three-Point, Low-Dose, Artery-Targeted Botulinum Toxin Treatment for Chronic Migraine: A Randomized, Double-Blind, Contralateral-Controlled Trial.
Aesthetic Plast Surg | 2026
Clinical trialSummary
Chronic migraine is a common condition affecting many people. This study focused on using low-dose botulinum toxin type A (BoNT-A) to treat it. Researchers wanted to see if targeted injections along migraine-related arteries could help. They involved 23 adults with chronic migraine in a controlled trial. Each participant received BoNT-A injections on one side of their head and saline on the other side. They measured pain intensity using a 10-point scale. Results showed that pain intensity on the treated side dropped significantly over two months. Specifically, scores decreased from 8.7 to 2.65, indicating a substantial improvement. Additionally, the study looked at changes in artery size, but those results were not highlighted. Overall, this research suggests that targeted BoNT-A injections can effectively reduce migraine pain in chronic sufferers. Clinical relevance: This study indicates that targeted botulinum toxin injections may significantly reduce chronic migraine pain, offering a new treatment option for patients seeking relief.
Key Learning Points
- Chronic migraine affects many individuals and can significantly impact their quality of life.
- Targeted injections of low-dose botulinum toxin type A may provide effective relief for chronic migraine sufferers.
- In a study, pain intensity decreased significantly from an average of 8.7 to 2.65 after treatment.
- The treatment involved comparing injections of botulinum toxin on one side of the head to saline on the other.
- This research offers a promising new option for patients looking for effective chronic migraine treatments.
Research Informatics
RANDOMISED CONTROLLED TRIAL
Botulinum toxin reduced migraine pain without arterial dilation.
safetyNo adverse events reported
follow Up2 months
conditionChronic migraine
populationAdults with chronic migraine
sample Size23
primary OutcomeReduction in headache intensity
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.